No photo of Kevin H Mayo
Contact Expert

View Scopus Profile

Kevin H Mayo

1979 …2020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 2 Similar Profiles
Nuclear magnetic resonance Chemical Compounds
Peptides Medicine & Life Sciences
Platelet Factor 4 Medicine & Life Sciences
Galectins Chemical Compounds
Galectin 1 Medicine & Life Sciences
Magnetic Resonance Spectroscopy Medicine & Life Sciences
Angiogenesis Inhibitors Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2002 2020

NMR studies of galectin antagonists

Mayo, K. H.

GALECTIN THERAPEUTICS, INC.

1/1/15 → 6/30/20

Project: Research project

antagonists

Molecular Mechanism of Action of BTI320

Mayo, K. H.

BOSTON THERAPEUTICS, INC.

4/1/17 → 3/31/18

Project: Research project

NMR studies of PAZ320 with sugar hydrolyzing enzymes

Mayo, K. H.

BOSTON THERAPEUTICS, INC.

10/1/13 → 3/31/15

Project: Research project

sugars
enzymes

Structure-Function Relationships in Galectins 1, 3, & 7

Mayo, K. H.

MN MED FDN

11/1/12 → 10/31/14

Project: Research project

Clinical Development of 0118 as a Therapeutic Against Ca

Mayo, K. H.

OncoEthix

6/1/08 → 5/31/13

Project: Research project

Neoplasms
Therapeutics

Research Output 1979 2019

1 Citation (Scopus)

A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1

Wook Park, S., Nhieu, J., Persaud, S. D., Miller, M. C., Xia, Y., Lin, Y. W., Lin, Y. L., Kagechika, H., Mayo, K. H. & Wei, L. N., Dec 1 2019, In : Scientific reports. 9, 1, 10929.

Research output: Contribution to journal › Article

Open Access
Retinoic Acid Receptors
Fibrosarcoma
Tretinoin
Phosphotransferases
Intercellular Signaling Peptides and Proteins

Corrigendum to “An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature” (Vaccine (2018) 36(21) (3054–3060), (S0264410X1830433X), (10.1016/j.vaccine.2018.03.064))

Huijbers, E. J. M., van Beijnum, J. R., Lê, C. T., Langman, S., Nowak-Sliwinska, P., Mayo, K. H. & Griffioen, A. W., Jul 9 2019, In : Vaccine. 37, 30, p. 4231-4232 2 p.

Research output: Contribution to journal › Comment/debate

Open Access
Conjugate Vaccines
Cancer Vaccines
Antibody Formation
vaccines
Technology
2 Citations (Scopus)

Galectin-3 binds selectively to the terminal, non-reducing end of β(1→4)-galactans, with overall affinity increasing with chain length

Miller, M. C., Zheng, Y., Zhou, Y., Tai, G. & Mayo, K. H., Jan 1 2019, In : Glycobiology. 29, 1, p. 74-84 11 p.

Research output: Contribution to journal › Article

Galactans
Galectin 3
Chain length
Carbohydrates
Galectins

Hybrid ligands with calixarene and thiodigalactoside groups: Galectin binding and cytotoxicity

Zhang, H., Ippel, H., Miller, M. C., Wong, T. J., Griffioen, A. W., Mayo, K. H. & Pieters, R. J., Aug 21 2019, In : Organic Chemistry Frontiers. 6, 16, p. 2981-2990 10 p.

Research output: Contribution to journal › Article

Calixarenes
Galectins
Cytotoxicity
Ligands
Galectin 1
1 Citation (Scopus)

NMR-based insight into galectin-3 binding to endothelial cell adhesion molecule CD146: Evidence for noncanonical interactions with the lectin's CRD β-sandwich F-face

Zhang, Z., Miller, M. C., Xu, X., Song, C., Zhang, F., Zheng, Y., Zhou, Y., Tai, G. & Mayo, K. H., Jul 19 2019, In : Glycobiology. 29, 8, p. 608-618 11 p.

Research output: Contribution to journal › Article

Galectin 3
Endothelial cells
Cell Adhesion Molecules
Lectins
Magnetic Resonance Spectroscopy